Pfizer

Page 34 of 37

Pfizer Inc. Headquarters As They Agree To Combine With Allergan Plc In $160 Billion Deal
Leadership

Here’s Why Allergan Shares Are Tanking

By
April 5, 2016
BRITAIN-BUSINESS-TAX-GOOGLE-US
Finance

April Fools: Beware of Jokes

By
April 1, 2016
Doctors Without Borders Protests High Cost Of Vaccines
Finance

Pfizer Just Got Pranked Big Time Before April Fool’s Day Even Started

By
March 31, 2016
Drugs From European Pharmaceuticals Companies As Stocks Outperformed The Stoxx 600 Index By 1.2 percentage Points
Health

Watchdog Says U.S. Big Pharma Isn’t Paying Enough for Breaking the Law

By
March 31, 2016
Why Teva’s $40 Billion Deal for Allergan’s Generic Drugs Is Being Delayed
Health

Why Teva’s $40 Billion Deal for Allergan’s Generic Drugs Is Being Delayed

By
March 16, 2016
Donald Trump
Leadership

Here Are the Companies Donald Trump Would Go After as President

By
March 16, 2016
Pfizer Inc. Headquarters As They Agree To Combine With Allergan Plc In $160 Billion Deal
Finance

Here’s How Much More Pfizer Could Save in Taxes With Allergan Deal

By
February 26, 2016
Pfizer In Merger Talks With Allergan PLC
Health

Generics and a Strong Dollar Are Cutting Into Pfizer’s Profits

By
February 2, 2016
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance

Biotech Stocks Crashed and Nobody Knows Why

By
January 29, 2016
Traders Work On The Floor NYSE As Stock Rout Deepens
Finance

Apple Is One of Only 5 Dow Stocks Up Today

By
January 20, 2016
Leaving Corporate America for a Startup: The Best Decision I Ever Made

Leaving Corporate America for a Startup: The Best Decision I Ever Made

By
January 13, 2016
Pfizer Inc. Headquarters As They Agree To Combine With Allergan Plc In $160 Billion Deal
Finance

2015 Is Now the Biggest Year Ever for M&A

By
December 4, 2015
ECB President Mario Draghi Rates Conference
Finance

Markets Fall On Draghi Misfire

By
December 4, 2015
Cindy Whitehead, chief executive officer of Sprout Pharmaceuticals Inc., speaks during a Bloomberg Television interview in New York, U.S., on Wednesday, Aug. 19, 2015. Whitehead discussed Addyi, the company's pill for low libido in women that won approval from the U.S. Food and Drug Administration yesterday. Photographer: Chris Goodney/Bloomberg *** Local Caption *** Cindy Whitehead
MPW

Sprout’s CEO On Why We Should Stop Calling Addyi ‘the Female Viagra’

By
December 2, 2015
Pfizer CEO Ian Read
Finance

Pfizer Says No Merger Tax Help For Our Top Execs

By
November 25, 2015

Most Popular